ONCOGEN PHARMA MALAYSIA SDN

Business Type: Manufacturer (Factory)

Company Profile:

Oncogen Pharma Malaysia Sdn Bhd is a licensed pharmaceutical manufacturing company specializing in the research, development, and production of oncology (cancer) drugs. It is a fully integrated pharmaceutical company with a state-of-the-art formulation research and manufacturing facility located in Techpark Enstek, Negeri Sembilan, Malaysia.

The company is established as a high-tech manufacturer rather than a trader. Its facility is designed to comply with stringent international regulatory standards, including US FDA, EU GMP, and PIC/S. Oncogen Pharma focuses on producing high-quality, affordable oncology products, including oral solids and injectables, to serve both domestic and global markets. By combining advanced scientific research with large-scale manufacturing capabilities, the company aims to ensure the accessibility of critical cancer therapies worldwide.

Key Information:

Establishment Year: 2014

Headquarters Location: Glenmarie, Shah Alam, Selangor, Malaysia

Manufacturing Plant Location: Techpark Enstek, Negeri Sembilan, Malaysia

Primary Industry: Pharmaceutical Manufacturing

Core Products: Oncology formulations (injectables and oral solid dosage forms)

Oncogen Pharma Malaysia SDN BHD Product Portfolio

Oncogen Pharma Malaysia specializes in the development and manufacture of high-potency oncology (cancer) products. Their portfolio includes Finished Dosage Formulations (FDFs) and High-Potency Active Pharmaceutical Ingredients (HPAPIs).

Finished Dosage Formulations

Oral Solid Dosages (Tablets and Capsules)

The company produces oral generic oncology medications, including:

Imatinib Tablets (used for leukemia and gastrointestinal stromal tumors)

Gefitinib Tablets (used for non-small cell lung cancer)

Erlotinib Tablets (used for pancreatic and lung cancer)

Temozolomide Capsules (used for brain tumors)

Capecitabine Tablets (used for breast and colorectal cancer)

Sterile Injectables (Liquid and Lyophilized Vials)

The company produces intravenous chemotherapy and targeted therapies, including:

Bortezomib for Injection (used for multiple myeloma)

Pemetrexed for Injection (used for lung cancer)

Gemcitabine Injection (used for pancreatic, lung, and breast cancer)

Decitabine for Injection (used for leukemia and blood disorders)

Azacitidine for Injection (used for blood disorders)

Docetaxel Injection (used for breast and prostate cancer)

High-Potency Active Pharmaceutical Ingredients (HPAPIs)

Oncogen Pharma also researches, develops, and manufactures the active raw drug substances (APIs) used to produce these oncology formulations.